Diagnosis and management of Parkinson’s disease dementia
Identifieur interne : 000C31 ( Main/Corpus ); précédent : 000C30; suivant : 000C32Diagnosis and management of Parkinson’s disease dementia
Auteurs : W. Poewe ; S. Gauthier ; D. Aarsland ; J. B. Leverenz ; P. Barone ; D. Weintraub ; E. Tolosa ; B. DuboisSource :
- International Journal of Clinical Practice [ 1368-5031 ] ; 2008-10.
Abstract
Parkinson’s disease (PD) has long been considered predominantly a motor disorder. However, its frequent association with dementia, which contributes significantly to the morbidity and mortality of the condition, is gaining increasing recognition. PD dementia (PDD) has a unique clinical profile and neuropathology, distinct from Alzheimer’s disease (AD). Cholinergic deficits, a feature of both AD and PDD, underlie the rationale for cholinesterase inhibitor therapy in both conditions. In clinical practice, it is important that PDD should be recognised and appropriately treated. This review aims to outline the recently proposed clinical diagnostic criteria for PDD and to summarise the guidelines/recommendations published since 2006 on the use of cholinesterase inhibitors in the management of PDD. Although the cholinesterase inhibitor rivastigmine has recently been approved for the management of PDD, there remains a need for the development of novel therapies that can affect key mechanisms of the disease or prevent/delay patients with PD and mild cognitive impairment from progressing to PDD.
Url:
DOI: 10.1111/j.1742-1241.2008.01869.x
Links to Exploration step
ISTEX:342A81FDDFC39E202423B5510B84C07AC8688AABLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Diagnosis and management of Parkinson’s disease dementia</title><author><name sortKey="Poewe, W" sort="Poewe, W" uniqKey="Poewe W" first="W." last="Poewe">W. Poewe</name><affiliation><mods:affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Gauthier, S" sort="Gauthier, S" uniqKey="Gauthier S" first="S." last="Gauthier">S. Gauthier</name><affiliation><mods:affiliation>Alzheimer’s Disease Research Unit, McGill Centre for Studies in Aging, Douglas Mental Health University Institute, Montréal, QC, Canada</mods:affiliation></affiliation></author><author><name sortKey="Aarsland, D" sort="Aarsland, D" uniqKey="Aarsland D" first="D." last="Aarsland">D. Aarsland</name><affiliation><mods:affiliation>Norweigen Centre for Movement Disorders, Stavenger University Hospital, Stavenger, Norway</mods:affiliation></affiliation><affiliation><mods:affiliation>Institute of Clinical Medicine, University of Bergen, Bergen, Norway</mods:affiliation></affiliation></author><author><name sortKey="Leverenz, J B" sort="Leverenz, J B" uniqKey="Leverenz J" first="J. B." last="Leverenz">J. B. Leverenz</name><affiliation><mods:affiliation>Mental Illness and Parkinson’s Disease Research Education and Clinical Centers, VA‐PSHCS, and Departments of Neurology and Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA</mods:affiliation></affiliation></author><author><name sortKey="Barone, P" sort="Barone, P" uniqKey="Barone P" first="P." last="Barone">P. Barone</name><affiliation><mods:affiliation>Dipartimento di Scienze Neurologiche, Università Federico II di Napoli, Naples, Italy</mods:affiliation></affiliation></author><author><name sortKey="Weintraub, D" sort="Weintraub, D" uniqKey="Weintraub D" first="D." last="Weintraub">D. Weintraub</name><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Tolosa, E" sort="Tolosa, E" uniqKey="Tolosa E" first="E." last="Tolosa">E. Tolosa</name><affiliation><mods:affiliation>Parkinson’s Disease and Movement Disorders Unit, Institut Clínic de Neurociències, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Dubois, B" sort="Dubois, B" uniqKey="Dubois B" first="B." last="Dubois">B. Dubois</name><affiliation><mods:affiliation>INSERM‐UPMC UMRS 610, Federation of Neurology, Salpêtrière Hospital; University of Paris, Paris, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:342A81FDDFC39E202423B5510B84C07AC8688AAB</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1111/j.1742-1241.2008.01869.x</idno><idno type="url">https://api.istex.fr/document/342A81FDDFC39E202423B5510B84C07AC8688AAB/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000C31</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Diagnosis and management of Parkinson’s disease dementia</title><author><name sortKey="Poewe, W" sort="Poewe, W" uniqKey="Poewe W" first="W." last="Poewe">W. Poewe</name><affiliation><mods:affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Gauthier, S" sort="Gauthier, S" uniqKey="Gauthier S" first="S." last="Gauthier">S. Gauthier</name><affiliation><mods:affiliation>Alzheimer’s Disease Research Unit, McGill Centre for Studies in Aging, Douglas Mental Health University Institute, Montréal, QC, Canada</mods:affiliation></affiliation></author><author><name sortKey="Aarsland, D" sort="Aarsland, D" uniqKey="Aarsland D" first="D." last="Aarsland">D. Aarsland</name><affiliation><mods:affiliation>Norweigen Centre for Movement Disorders, Stavenger University Hospital, Stavenger, Norway</mods:affiliation></affiliation><affiliation><mods:affiliation>Institute of Clinical Medicine, University of Bergen, Bergen, Norway</mods:affiliation></affiliation></author><author><name sortKey="Leverenz, J B" sort="Leverenz, J B" uniqKey="Leverenz J" first="J. B." last="Leverenz">J. B. Leverenz</name><affiliation><mods:affiliation>Mental Illness and Parkinson’s Disease Research Education and Clinical Centers, VA‐PSHCS, and Departments of Neurology and Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA</mods:affiliation></affiliation></author><author><name sortKey="Barone, P" sort="Barone, P" uniqKey="Barone P" first="P." last="Barone">P. Barone</name><affiliation><mods:affiliation>Dipartimento di Scienze Neurologiche, Università Federico II di Napoli, Naples, Italy</mods:affiliation></affiliation></author><author><name sortKey="Weintraub, D" sort="Weintraub, D" uniqKey="Weintraub D" first="D." last="Weintraub">D. Weintraub</name><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Tolosa, E" sort="Tolosa, E" uniqKey="Tolosa E" first="E." last="Tolosa">E. Tolosa</name><affiliation><mods:affiliation>Parkinson’s Disease and Movement Disorders Unit, Institut Clínic de Neurociències, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Dubois, B" sort="Dubois, B" uniqKey="Dubois B" first="B." last="Dubois">B. Dubois</name><affiliation><mods:affiliation>INSERM‐UPMC UMRS 610, Federation of Neurology, Salpêtrière Hospital; University of Paris, Paris, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">International Journal of Clinical Practice</title><idno type="ISSN">1368-5031</idno><idno type="eISSN">1742-1241</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2008-10">2008-10</date><biblScope unit="volume">62</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1581">1581</biblScope><biblScope unit="page" to="1587">1587</biblScope></imprint><idno type="ISSN">1368-5031</idno></series><idno type="istex">342A81FDDFC39E202423B5510B84C07AC8688AAB</idno><idno type="DOI">10.1111/j.1742-1241.2008.01869.x</idno><idno type="ArticleID">IJCP1869</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1368-5031</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson’s disease (PD) has long been considered predominantly a motor disorder. However, its frequent association with dementia, which contributes significantly to the morbidity and mortality of the condition, is gaining increasing recognition. PD dementia (PDD) has a unique clinical profile and neuropathology, distinct from Alzheimer’s disease (AD). Cholinergic deficits, a feature of both AD and PDD, underlie the rationale for cholinesterase inhibitor therapy in both conditions. In clinical practice, it is important that PDD should be recognised and appropriately treated. This review aims to outline the recently proposed clinical diagnostic criteria for PDD and to summarise the guidelines/recommendations published since 2006 on the use of cholinesterase inhibitors in the management of PDD. Although the cholinesterase inhibitor rivastigmine has recently been approved for the management of PDD, there remains a need for the development of novel therapies that can affect key mechanisms of the disease or prevent/delay patients with PD and mild cognitive impairment from progressing to PDD.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>W. Poewe</name><affiliations><json:string>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>S. Gauthier</name><affiliations><json:string>Alzheimer’s Disease Research Unit, McGill Centre for Studies in Aging, Douglas Mental Health University Institute, Montréal, QC, Canada</json:string></affiliations></json:item><json:item><name>D. Aarsland</name><affiliations><json:string>Norweigen Centre for Movement Disorders, Stavenger University Hospital, Stavenger, Norway</json:string><json:string>Institute of Clinical Medicine, University of Bergen, Bergen, Norway</json:string></affiliations></json:item><json:item><name>J. B. Leverenz</name><affiliations><json:string>Mental Illness and Parkinson’s Disease Research Education and Clinical Centers, VA‐PSHCS, and Departments of Neurology and Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA</json:string></affiliations></json:item><json:item><name>P. Barone</name><affiliations><json:string>Dipartimento di Scienze Neurologiche, Università Federico II di Napoli, Naples, Italy</json:string></affiliations></json:item><json:item><name>D. Weintraub</name><affiliations><json:string>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA</json:string></affiliations></json:item><json:item><name>E. Tolosa</name><affiliations><json:string>Parkinson’s Disease and Movement Disorders Unit, Institut Clínic de Neurociències, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain</json:string></affiliations></json:item><json:item><name>B. Dubois</name><affiliations><json:string>INSERM‐UPMC UMRS 610, Federation of Neurology, Salpêtrière Hospital; University of Paris, Paris, France</json:string></affiliations></json:item></author><articleId><json:string>IJCP1869</json:string></articleId><language><json:string>eng</json:string></language><abstract>Parkinson’s disease (PD) has long been considered predominantly a motor disorder. However, its frequent association with dementia, which contributes significantly to the morbidity and mortality of the condition, is gaining increasing recognition. PD dementia (PDD) has a unique clinical profile and neuropathology, distinct from Alzheimer’s disease (AD). Cholinergic deficits, a feature of both AD and PDD, underlie the rationale for cholinesterase inhibitor therapy in both conditions. In clinical practice, it is important that PDD should be recognised and appropriately treated. This review aims to outline the recently proposed clinical diagnostic criteria for PDD and to summarise the guidelines/recommendations published since 2006 on the use of cholinesterase inhibitors in the management of PDD. Although the cholinesterase inhibitor rivastigmine has recently been approved for the management of PDD, there remains a need for the development of novel therapies that can affect key mechanisms of the disease or prevent/delay patients with PD and mild cognitive impairment from progressing to PDD.</abstract><qualityIndicators><score>6.239</score><pdfVersion>1.3</pdfVersion><pdfPageSize>595.276 x 782.362 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1103</abstractCharCount><pdfWordCount>4355</pdfWordCount><pdfCharCount>28908</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>157</abstractWordCount></qualityIndicators><title>Diagnosis and management of Parkinson’s disease dementia</title><genre><json:string>review-article</json:string></genre><host><volume>62</volume><publisherId><json:string>IJCP</json:string></publisherId><pages><total>7</total><last>1587</last><first>1581</first></pages><issn><json:string>1368-5031</json:string></issn><issue>10</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1742-1241</json:string></eissn><title>International Journal of Clinical Practice</title><doi><json:string>10.1111/(ISSN)1742-1241</json:string></doi></host><publicationDate>2008</publicationDate><copyrightDate>2008</copyrightDate><doi><json:string>10.1111/j.1742-1241.2008.01869.x</json:string></doi><id>342A81FDDFC39E202423B5510B84C07AC8688AAB</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/342A81FDDFC39E202423B5510B84C07AC8688AAB/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/342A81FDDFC39E202423B5510B84C07AC8688AAB/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/342A81FDDFC39E202423B5510B84C07AC8688AAB/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Diagnosis and management of Parkinson’s disease dementia</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>2008</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Diagnosis and management of Parkinson’s disease dementia</title><author><persName><forename type="first">W.</forename><surname>Poewe</surname></persName><affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</affiliation></author><author><persName><forename type="first">S.</forename><surname>Gauthier</surname></persName><affiliation>Alzheimer’s Disease Research Unit, McGill Centre for Studies in Aging, Douglas Mental Health University Institute, Montréal, QC, Canada</affiliation></author><author><persName><forename type="first">D.</forename><surname>Aarsland</surname></persName><affiliation>Norweigen Centre for Movement Disorders, Stavenger University Hospital, Stavenger, Norway</affiliation><affiliation>Institute of Clinical Medicine, University of Bergen, Bergen, Norway</affiliation></author><author><persName><forename type="first">J. B.</forename><surname>Leverenz</surname></persName><affiliation>Mental Illness and Parkinson’s Disease Research Education and Clinical Centers, VA‐PSHCS, and Departments of Neurology and Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA</affiliation></author><author><persName><forename type="first">P.</forename><surname>Barone</surname></persName><affiliation>Dipartimento di Scienze Neurologiche, Università Federico II di Napoli, Naples, Italy</affiliation></author><author><persName><forename type="first">D.</forename><surname>Weintraub</surname></persName><affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA</affiliation></author><author><persName><forename type="first">E.</forename><surname>Tolosa</surname></persName><affiliation>Parkinson’s Disease and Movement Disorders Unit, Institut Clínic de Neurociències, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain</affiliation></author><author><persName><forename type="first">B.</forename><surname>Dubois</surname></persName><affiliation>INSERM‐UPMC UMRS 610, Federation of Neurology, Salpêtrière Hospital; University of Paris, Paris, France</affiliation></author></analytic><monogr><title level="j">International Journal of Clinical Practice</title><idno type="pISSN">1368-5031</idno><idno type="eISSN">1742-1241</idno><idno type="DOI">10.1111/(ISSN)1742-1241</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2008-10"></date><biblScope unit="volume">62</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1581">1581</biblScope><biblScope unit="page" to="1587">1587</biblScope></imprint></monogr><idno type="istex">342A81FDDFC39E202423B5510B84C07AC8688AAB</idno><idno type="DOI">10.1111/j.1742-1241.2008.01869.x</idno><idno type="ArticleID">IJCP1869</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2008</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Parkinson’s disease (PD) has long been considered predominantly a motor disorder. However, its frequent association with dementia, which contributes significantly to the morbidity and mortality of the condition, is gaining increasing recognition. PD dementia (PDD) has a unique clinical profile and neuropathology, distinct from Alzheimer’s disease (AD). Cholinergic deficits, a feature of both AD and PDD, underlie the rationale for cholinesterase inhibitor therapy in both conditions. In clinical practice, it is important that PDD should be recognised and appropriately treated. This review aims to outline the recently proposed clinical diagnostic criteria for PDD and to summarise the guidelines/recommendations published since 2006 on the use of cholinesterase inhibitors in the management of PDD. Although the cholinesterase inhibitor rivastigmine has recently been approved for the management of PDD, there remains a need for the development of novel therapies that can affect key mechanisms of the disease or prevent/delay patients with PD and mild cognitive impairment from progressing to PDD.</p></abstract></profileDesc><revisionDesc><change when="2008-10">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/342A81FDDFC39E202423B5510B84C07AC8688AAB/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1742-1241</doi><issn type="print">1368-5031</issn><issn type="electronic">1742-1241</issn><idGroup><id type="product" value="IJCP"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="INTERNATIONAL JOURNAL OF CLINICAL PRACTICE">International Journal of Clinical Practice</title></titleGroup></publicationMeta><publicationMeta level="part" position="10010"><doi origin="wiley">10.1111/ijcp.2008.62.issue-10</doi><numberingGroup><numbering type="journalVolume" number="62">62</numbering><numbering type="journalIssue" number="10">10</numbering></numberingGroup><coverDate startDate="2008-10">October 2008</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="18" status="forIssue" accessType="open"><doi origin="wiley">10.1111/j.1742-1241.2008.01869.x</doi><idGroup><id type="unit" value="IJCP1869"></id><id type="supplier" value="1869"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="tocHeading1">Review Articles</title></titleGroup><copyright>© 2008 The Authors. Journal compilation © 2008 Blackwell Publishing Ltd</copyright><eventGroup><event type="firstOnline" date="2008-09-08"></event><event type="publishedOnlineFinalForm" date="2008-09-08"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.6 mode:FullText source:FullText result:FullText" date="2010-05-18"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-13"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-24"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="1581">1581</numbering><numbering type="pageLast" number="1587">1587</numbering></numberingGroup><correspondenceTo>Professor Werner Poewe
Department of Neurology, Medical University Innsbruck, Anichstraße 35, A‐6020 Innsbruck, Austria
Tel.: + 43 512 504 23850
Fax: + 43 512 504 23852
Email: <email>werner.poewe@uibk.ac.at</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:IJCP.IJCP1869.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Paper received May 2008, accepted July 2008</unparsedEditorialHistory><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="4"></count></countGroup><titleGroup><title type="main">Diagnosis and management of Parkinson’s disease dementia</title><title type="shortAuthors">Diagnosis and management of PDD</title><title type="short">Diagnosis and management of PDD</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>W.</givenNames><familyName>Poewe</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a2"><personName><givenNames>S.</givenNames><familyName>Gauthier</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a3 #a4"><personName><givenNames>D.</givenNames><familyName>Aarsland</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a5"><personName><givenNames>J. B.</givenNames><familyName>Leverenz</familyName></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a6"><personName><givenNames>P.</givenNames><familyName>Barone</familyName></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#a7"><personName><givenNames>D.</givenNames><familyName>Weintraub</familyName></personName></creator><creator creatorRole="author" xml:id="cr7" affiliationRef="#a8"><personName><givenNames>E.</givenNames><familyName>Tolosa</familyName></personName></creator><creator creatorRole="author" xml:id="cr8" affiliationRef="#a9"><personName><givenNames>B.</givenNames><familyName>Dubois</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="AT"><unparsedAffiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="CA"><unparsedAffiliation>Alzheimer’s Disease Research Unit, McGill Centre for Studies in Aging, Douglas Mental Health University Institute, Montréal, QC, Canada</unparsedAffiliation></affiliation><affiliation xml:id="a3" countryCode="NO"><unparsedAffiliation>Norweigen Centre for Movement Disorders, Stavenger University Hospital, Stavenger, Norway</unparsedAffiliation></affiliation><affiliation xml:id="a4" countryCode="NO"><unparsedAffiliation>Institute of Clinical Medicine, University of Bergen, Bergen, Norway</unparsedAffiliation></affiliation><affiliation xml:id="a5" countryCode="US"><unparsedAffiliation>Mental Illness and Parkinson’s Disease Research Education and Clinical Centers, VA‐PSHCS, and Departments of Neurology and Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA</unparsedAffiliation></affiliation><affiliation xml:id="a6" countryCode="IT"><unparsedAffiliation>Dipartimento di Scienze Neurologiche, Università Federico II di Napoli, Naples, Italy</unparsedAffiliation></affiliation><affiliation xml:id="a7" countryCode="US"><unparsedAffiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA</unparsedAffiliation></affiliation><affiliation xml:id="a8" countryCode="ES"><unparsedAffiliation>Parkinson’s Disease and Movement Disorders Unit, Institut Clínic de Neurociències, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain</unparsedAffiliation></affiliation><affiliation xml:id="a9" countryCode="FR"><unparsedAffiliation>INSERM‐UPMC UMRS 610, Federation of Neurology, Salpêtrière Hospital; University of Paris, Paris, France</unparsedAffiliation></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Summary</title><p>Parkinson’s disease (PD) has long been considered predominantly a motor disorder. However, its frequent association with dementia, which contributes significantly to the morbidity and mortality of the condition, is gaining increasing recognition. PD dementia (PDD) has a unique clinical profile and neuropathology, distinct from Alzheimer’s disease (AD). Cholinergic deficits, a feature of both AD and PDD, underlie the rationale for cholinesterase inhibitor therapy in both conditions. In clinical practice, it is important that PDD should be recognised and appropriately treated. This review aims to outline the recently proposed clinical diagnostic criteria for PDD and to summarise the guidelines/recommendations published since 2006 on the use of cholinesterase inhibitors in the management of PDD. Although the cholinesterase inhibitor rivastigmine has recently been approved for the management of PDD, there remains a need for the development of novel therapies that can affect key mechanisms of the disease or prevent/delay patients with PD and mild cognitive impairment from progressing to PDD.</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1" numbered="no"><p> <b>Disclosures</b>
SG has been a consultant and is an investigator in Novartis‐sponsored studies, he owns no stock or option; DA has received honoraria and research support from Novartis, Pfizer, Janssen‐Cilag, H. Lundbeck, AstraZeneca, he owns no stock or option; JBL has been a consultant for GlaxoSmithKline, and consultant and speaker for Novartis Pharmaceuticals; DW has served as a consultant to Novartis.</p></note><note xml:id="fn2" numbered="no"><p>Re‐use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Diagnosis and management of Parkinson’s disease dementia</title></titleInfo><titleInfo type="abbreviated"><title>Diagnosis and management of PDD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Diagnosis and management of Parkinson’s disease dementia</title></titleInfo><name type="personal"><namePart type="given">W.</namePart><namePart type="family">Poewe</namePart><affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Gauthier</namePart><affiliation>Alzheimer’s Disease Research Unit, McGill Centre for Studies in Aging, Douglas Mental Health University Institute, Montréal, QC, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D.</namePart><namePart type="family">Aarsland</namePart><affiliation>Norweigen Centre for Movement Disorders, Stavenger University Hospital, Stavenger, Norway</affiliation><affiliation>Institute of Clinical Medicine, University of Bergen, Bergen, Norway</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. B.</namePart><namePart type="family">Leverenz</namePart><affiliation>Mental Illness and Parkinson’s Disease Research Education and Clinical Centers, VA‐PSHCS, and Departments of Neurology and Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Barone</namePart><affiliation>Dipartimento di Scienze Neurologiche, Università Federico II di Napoli, Naples, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D.</namePart><namePart type="family">Weintraub</namePart><affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Tolosa</namePart><affiliation>Parkinson’s Disease and Movement Disorders Unit, Institut Clínic de Neurociències, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Dubois</namePart><affiliation>INSERM‐UPMC UMRS 610, Federation of Neurology, Salpêtrière Hospital; University of Paris, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2008-10</dateIssued><edition>Paper received May 2008, accepted July 2008</edition><copyrightDate encoding="w3cdtf">2008</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">4</extent></physicalDescription><abstract lang="en">Parkinson’s disease (PD) has long been considered predominantly a motor disorder. However, its frequent association with dementia, which contributes significantly to the morbidity and mortality of the condition, is gaining increasing recognition. PD dementia (PDD) has a unique clinical profile and neuropathology, distinct from Alzheimer’s disease (AD). Cholinergic deficits, a feature of both AD and PDD, underlie the rationale for cholinesterase inhibitor therapy in both conditions. In clinical practice, it is important that PDD should be recognised and appropriately treated. This review aims to outline the recently proposed clinical diagnostic criteria for PDD and to summarise the guidelines/recommendations published since 2006 on the use of cholinesterase inhibitors in the management of PDD. Although the cholinesterase inhibitor rivastigmine has recently been approved for the management of PDD, there remains a need for the development of novel therapies that can affect key mechanisms of the disease or prevent/delay patients with PD and mild cognitive impairment from progressing to PDD.</abstract><relatedItem type="host"><titleInfo><title>International Journal of Clinical Practice</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">1368-5031</identifier><identifier type="eISSN">1742-1241</identifier><identifier type="DOI">10.1111/(ISSN)1742-1241</identifier><identifier type="PublisherID">IJCP</identifier><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><detail type="issue"><caption>no.</caption><number>10</number></detail><extent unit="pages"><start>1581</start><end>1587</end><total>7</total></extent></part></relatedItem><identifier type="istex">342A81FDDFC39E202423B5510B84C07AC8688AAB</identifier><identifier type="DOI">10.1111/j.1742-1241.2008.01869.x</identifier><identifier type="ArticleID">IJCP1869</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2008 The Authors. Journal compilation © 2008 Blackwell Publishing Ltd</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C31 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000C31 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:342A81FDDFC39E202423B5510B84C07AC8688AAB
|texte= Diagnosis and management of Parkinson’s disease dementia
}}
| This area was generated with Dilib version V0.6.23. |  |